Canonical solution label for systems where the primary value is continuous interpretation of regulations, policy controls, and compliance workflows rather than a single implementation technique.
Automates a large share of case-level drug coding to reduce manual pharmacovigilance workload Evidence basis: WHODrug Koda evaluation on 4.8 million VigiBase entries reported major automation gains with high coding accuracy; additional NLP work supports scalable coding from unstructured narratives with expert oversight for exceptions
Surfaces probable ADEs from unstructured records to prioritize pharmacovigilance review Evidence basis: Recent Drug Safety reviews report consistent progress in NLP and ML ADE detection from free-text narratives; evidence supports faster triage and broader coverage while transportability varies by dataset quality
Maps label language to MedDRA terms to speed identification of potentially unlabeled case signals Evidence basis: FDA-associated evaluations showed NLP can map adverse-event terms in labels to MedDRA with practical precision and recall; shared-task results indicate strong triage support but not full replacement of expert safety review
Standardizes model-risk and context-of-use evidence packages for AI-enabled submission components Evidence basis: FDA draft guidance introduces a risk-based credibility assessment workflow for AI used in drug and biologic regulatory support; EMA reflection guidance aligns on lifecycle governance transparency and context-specific validation
Continuously tracks and classifies new guidance changes to reduce missed compliance updates Evidence basis: FDA EMA and ICH have issued multiple AI and adaptive-design updates from 2023 to 2025 indicating a rapidly changing requirement landscape; automation is most defensible as a compliance process accelerator rather than a direct clinical outcome driver